94 related articles for article (PubMed ID: 22926517)
1. miR-100 suppresses IGF2 and inhibits breast tumorigenesis by interfering with proliferation and survival signaling.
Gebeshuber CA; Martinez J
Oncogene; 2013 Jul; 32(27):3306-10. PubMed ID: 22926517
[TBL] [Abstract][Full Text] [Related]
2. 3,6-Dihydroxyflavone Suppresses Breast Carcinogenesis by Epigenetically Regulating miR-34a and miR-21.
Peng X; Chang H; Gu Y; Chen J; Yi L; Xie Q; Zhu J; Zhang Q; Mi M
Cancer Prev Res (Phila); 2015 Jun; 8(6):509-17. PubMed ID: 25784176
[TBL] [Abstract][Full Text] [Related]
3. Impact of constitutive IGF1/IGF2 stimulation on the transcriptional program of human breast cancer cells.
Pacher M; Seewald MJ; Mikula M; Oehler S; Mogg M; Vinatzer U; Eger A; Schweifer N; Varecka R; Sommergruber W; Mikulits W; Schreiber M
Carcinogenesis; 2007 Jan; 28(1):49-59. PubMed ID: 16774935
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways.
Oneyama C; Ikeda J; Okuzaki D; Suzuki K; Kanou T; Shintani Y; Morii E; Okumura M; Aozasa K; Okada M
Oncogene; 2011 Aug; 30(32):3489-501. PubMed ID: 21383697
[TBL] [Abstract][Full Text] [Related]
5. MiR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma.
Law PT; Ching AK; Chan AW; Wong QW; Wong CK; To KF; Wong N
Carcinogenesis; 2012 Jun; 33(6):1134-41. PubMed ID: 22431718
[TBL] [Abstract][Full Text] [Related]
6. miR-296/Scribble axis is deregulated in human breast cancer and miR-296 restoration reduces tumour growth in vivo.
Savi F; Forno I; Faversani A; Luciani A; Caldiera S; Gatti S; Foa P; Ricca D; Bulfamante G; Vaira V; Bosari S
Clin Sci (Lond); 2014 Aug; 127(4):233-42. PubMed ID: 24527800
[TBL] [Abstract][Full Text] [Related]
7. MiR-98-5p/IGF2 Axis Influence Herceptin Sensitivity through IGF1R/HER2 Heterodimer Formation and AKT/mTOR Signal Pathway in HER2 Positive Breast Cancer.
Zhang M; Li Z; Liu X
Asian Pac J Cancer Prev; 2021 Nov; 22(11):3693-3703. PubMed ID: 34837929
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-494 downregulates KIT and inhibits gastrointestinal stromal tumor cell proliferation.
Kim WK; Park M; Kim YK; Tae YK; Yang HK; Lee JM; Kim H
Clin Cancer Res; 2011 Dec; 17(24):7584-94. PubMed ID: 22042971
[TBL] [Abstract][Full Text] [Related]
9. Development of microRNA-145 for therapeutic application in breast cancer.
Kim SJ; Oh JS; Shin JY; Lee KD; Sung KW; Nam SJ; Chun KH
J Control Release; 2011 Nov; 155(3):427-34. PubMed ID: 21723890
[TBL] [Abstract][Full Text] [Related]
10. Long non-coding RNA IGF2-AS represses breast cancer tumorigenesis by epigenetically regulating IGF2.
Zhang Y; Yan H; Jiang Y; Chen T; Ma Z; Li F; Lin M; Xu Y; Zhang X; Zhang J; He H
Exp Biol Med (Maywood); 2021 Feb; 246(4):371-379. PubMed ID: 33175607
[TBL] [Abstract][Full Text] [Related]
11. Dysregulation of the BRCA1/long non-coding RNA NEAT1 signaling axis contributes to breast tumorigenesis.
Lo PK; Zhang Y; Wolfson B; Gernapudi R; Yao Y; Duru N; Zhou Q
Oncotarget; 2016 Oct; 7(40):65067-65089. PubMed ID: 27556296
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone.
Liu S; Goldstein RH; Scepansky EM; Rosenblatt M
Cancer Res; 2009 Nov; 69(22):8742-51. PubMed ID: 19887617
[TBL] [Abstract][Full Text] [Related]
13. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
15. Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2.
Chao A; Lin CY; Lee YS; Tsai CL; Wei PC; Hsueh S; Wu TI; Tsai CN; Wang CJ; Chao AS; Wang TH; Lai CH
Oncogene; 2012 Feb; 31(6):764-75. PubMed ID: 21725366
[TBL] [Abstract][Full Text] [Related]
16. IGF2 mRNA binding protein-2 is a tumor promoter that drives cancer proliferation through its client mRNAs IGF2 and HMGA1.
Dai N; Ji F; Wright J; Minichiello L; Sadreyev R; Avruch J
Elife; 2017 Jul; 6():. PubMed ID: 28753127
[TBL] [Abstract][Full Text] [Related]
17. Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer.
Luo L; Zhang Z; Qiu N; Ling L; Jia X; Song Y; Li H; Li J; Lyu H; Liu H; He Z; Liu B; Zheng G
Nat Commun; 2021 May; 12(1):2699. PubMed ID: 33976188
[TBL] [Abstract][Full Text] [Related]
18. Loss of the Opa interacting protein 5 inhibits breast cancer proliferation through miR-139-5p/NOTCH1 pathway.
Li HC; Chen YF; Feng W; Cai H; Mei Y; Jiang YM; Chen T; Xu K; Feng DX
Gene; 2017 Mar; 603():1-8. PubMed ID: 27916718
[TBL] [Abstract][Full Text] [Related]
19. The miR-17∼92 microRNA Cluster Is a Global Regulator of Tumor Metabolism.
Izreig S; Samborska B; Johnson RM; Sergushichev A; Ma EH; Lussier C; Loginicheva E; Donayo AO; Poffenberger MC; Sagan SM; Vincent EE; Artyomov MN; Duchaine TF; Jones RG
Cell Rep; 2016 Aug; 16(7):1915-28. PubMed ID: 27498867
[TBL] [Abstract][Full Text] [Related]
20. miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis.
Gebeshuber CA; Zatloukal K; Martinez J
EMBO Rep; 2009 Apr; 10(4):400-5. PubMed ID: 19247375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
